3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
18
Breast Neoplasms
17
Advanced Solid Tumors
16
Advanced Solid Tumor
12
Carcinoma, Non-Small-Cell Lung
10
Myelodysplastic Syndromes
8
Solid Tumor
6
Recurrence
6
Prostatic Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
5
Ovarian Neoplasms
5
Carcinoma, Hepatocellular
5
Small Cell Lung Carcinoma
4
Myeloproliferative Disorders
4
Multiple Myeloma
4
Advanced Solid Tumour
4
Advanced Malignant Solid Tumor
4
Solid Tumors
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myelomonocytic, Chronic
3
Biliary Tract Neoplasms
3
Advanced Lung Cancer
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Interventions
Cisplatin
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
Paclitaxel
6
Platinum
5
Cyclophosphamide
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
4
durvalumab
4
cemiplimab
4
Radiotherapy, Intensity-Modulated
4
Radiotherapy
3
Pemetrexed
3
Oxaliplatin
3
Nivolumab
3
Fluorouracil
3
Cetuximab
3
Carboplatin
3
Biopsy
3
poly ICLC
2
fludarabine phosphate
2
cabozantinib
2
atezolizumab
2
Radiation
2
Ipilimumab
2
Interviews as Topic
2
Heavy Ion Radiotherapy
2
Gemcitabine
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma
×
Injections
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled